Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00161) | |||||
---|---|---|---|---|---|
Name |
Cysteamine
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
CYSTEAMINE; 2-Aminoethanethiol; Mercaptamine; 60-23-1; Thioethanolamine; Becaptan; Mercamine; Cysteinamine; beta-Mercaptoethylamine; 2-Mercaptoethylamine; Cysteamin; Lambraten; Lambratene; beta-Aminoethanethiol; Cystagon; Riacon; Decarboxycysteine; Mercaptoethylamine; 2-Amino-1-ethanethiol; Ethanethiol, 2-amino-; Cisteamina; 2-Aminoethyl mercaptan; beta-Aminoethylthiol; 2-Mercaptoethanamine; Mercaptamin; (2-Mercaptoethyl)amine; MEA (mercaptan); Ethanethiolamine; 2-AMINO-ETHANETHIOL; beta-MEA; Aminoethyl mercaptan; Mercaptamina; Mercaptaminum; Cysteamide; Mecramine; Mercamin; Merkamin; Cisteamina [Italian]; Cystaran; Mercaptaminum [INN-Latin]; Mercaptamina [INN-Spanish]; 1-Amino-2-mercaptoethylamine; L-1573; Cysteamine (USAN); WR 347; 2-aminoethane-1-thiol; UNII-5UX2SD1KE2; NSC 647528; Cysteamine [USAN]; Mercaptamine (INN); .beta.-Mercaptoethylamine; 5UX2SD1KE2; CHEBI:17141; 2-aminoethane-1-thiol; Cysteamine; Mercaptamine [INN]; NSC647528; NSC-647528; NCGC00015691-03; 2-Aminoethanethiol, 95%; Cysteamine [USAN:BAN]; beta-Mercaptoethylamine;2-Aminoethanethiol;2-Mercaptoethylamine; C2H7NS; Cysteamine bitartate; CCRIS 3083; HSDB 7353; EINECS 200-463-0; L 1573; Cystagone; b-Aminoethylthiol; 2-aminoethanethio; b-Aminoethanethiol; mercapto ethylamine; b-Mercaptoethylamine; MFCD00008196; 2-amino-ethyl thiol; .beta.-MEA; Cysteamine, ~95%; Cysteamine, free base; .beta.-Aminoethylthiol; Spectrum_001755; .beta.-Aminoethanethiol; ACMC-1AVBC; SpecPlus_000654; (Mercaptoethyl)ammonium toluene-p-sulphonate; Lopac-M-6500; DSSTox_CID_2875; bmse000388; CHEMBL602; C-9500; DSSTox_RID_76770; DSSTox_GSID_22875; KBioSS_002235; DivK1c_006750; 2-$l^{1}-sulfanylethanamine; BDBM7968; GTPL7440; 2,3-DESHYDROLANTHIONINE; DTXSID3022875; KBio1_001694; KBio2_002235; KBio2_004803; KBio2_007371; Cysteamine, >=98.0% (RT); BCP15015; ZINC8034121; EINECS 221-235-7; Tox21_113092; ANW-33452; HY-77591A; STK315355; AKOS003793343; CCG-204834; DB00847; MCULE-1838427828; NE18622; SDCCGSBI-0050727.P004; CAS-60-23-1; NCGC00015691-01; NCGC00015691-02; NCGC00015691-04; NCGC00015691-14; NCGC00162236-01; NCGC00162236-02; AS-56218; BP-13401; NCI60_002000; SBI-0050727.P003; AB0020070; DB-053562; FT-0611243; C01678; D03634; AB00053754_09; AB00053754_10; 106791-EP2292597A1; 106791-EP2295407A1; 106791-EP2298736A1; 213515-EP2371809A1; Cysteamine, 2-Mercaptoethylamine, Thioethanolamine; Q617563; F0001-1576; 2DFDA1F8-7010-4225-8280-AB1C4C43F546
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Nephropathic cystinosis | ICD-11: 5C60 | [1] | ||
PubChem CID | |||||
Formula |
C2H7NS
|
||||
Canonical SMILES |
C(CS)N
|
||||
InChI |
1S/C2H7NS/c3-1-2-4/h4H,1-3H2
|
||||
InChIKey |
UFULAYFCSOUIOV-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=6058"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 77.15 | Topological Polar Surface Area | 27 | |
XlogP | -0.4 | Complexity | 10 | ||
Heavy Atom Count | 4 | Rotatable Bond Count | 1 | ||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 2 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Cysteamine 150 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Ammonia; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Silicon dioxide; Gelatin, unspecified; Microcrystalline cellulose; Starch, corn
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Mylan Pharamceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Cysteamine 50 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Ammonia; Ferrosoferric oxide; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Silicon dioxide; Gelatin, unspecified; Microcrystalline cellulose; Starch, corn
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Mylan Pharamceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Cysteamine 25 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Fd&c blue no. 2; Talc; Titanium dioxide; Triethyl citrate; Water; Cellulose, microcrystalline; Gelatin; Hypromelloses; Methacrylic acid - ethyl acrylate copolymer (1:1) type a
|
|||||
Dosage Form | Delayed Release Oral Capsule | |||||
Company | Raptor Therapeutics | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [5] | |||
Cysteamine 75 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Fd&c blue no. 2; Talc; Titanium dioxide; Triethyl citrate; Water; Cellulose, microcrystalline; Gelatin; Hypromelloses; Methacrylic acid - ethyl acrylate copolymer (1:1) type a
|
|||||
Dosage Form | Delayed Release Oral Capsule | |||||
Company | Raptor Therapeutics | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [5] | |||
Cysteamine Bitartrate eq 50mg base capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Ammonium Hydroxide; Black Iron Oxide; Colloidal Silicon Dioxide; Croscarmellose Sodium; Gelatin; Magnesium Stearate; Microcrystalline Cellulose; Pharmaceutical Glaze; Pregelatinized Starch; Propylene Glycol; Sodium Lauryl Sulfate; Titanium Dioxide
|
|||||
Dosage Form | Capsule | |||||
Company | Mylan Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [3] | |||
Gelatin | DIG Info | Mephenytoin 4-hydroxylase (EC50 = 20.5 uM) | [6] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Pregelatinized starch | DIG Info | Multidrug resistance protein 1 (Protein expression downregulation) | [4] | |||
Cysteamine Bitartrate eq 75mg base capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Gelatin; Ink (Blue And White); Titanium Dioxide
|
|||||
Dosage Form | Capsule | |||||
Company | Horizon Therapeutics Usa | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Gelatin | DIG Info | Mephenytoin 4-hydroxylase (EC50 = 20.5 uM) | [6] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.